R,S-N-Methoxycarbonyl-2-(3-methoxyphenyl)-glycine | 261524-25-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: R,S-N-Methoxycarbonyl-2-(3-methoxyphenyl)-glycine
• 英文别名: N-Methoxycarbonyl-2-(3-methoxyphenyl)glycine；Methoxycarbonylamino-(3-methoxy-phenyl)-acetic acid；2-(methoxycarbonylamino)-2-(3-methoxyphenyl)acetic acid
• CAS: 261524-25-8
• 化学式: C₁₁H₁₃NO₅
• 分子量: 239.228
• InChiKey: CSNCHEVKUIPVLM-UHFFFAOYSA-N

物化性质

• 沸点：
  428.5±45.0 °C(Predicted)
• 密度：
  1.279±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  84.9
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  R,S-N-Methoxycarbonyl-2-(3-methoxyphenyl)-glycine 在 盐酸 、 lithium aluminium tetrahydride 、 三溴化硼 、 potassium carbonate 、 1-羟基苯并三唑 、 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 ADL 01-0344
  参考文献：
  名称：

  Synthesis and evaluation of novel peripherally restricted κ-opioid receptor agonists

  摘要：

  A series of 3-substituted analogs (3) of the parent K agonist, 1, were prepared to limit access to the central nervous system. With the exception of compound 3j, all other compounds bound to the human K opioid receptor with high affinity (K-i = 0.31-9.5 nM) and were selective for K over mu and 6 opioid receptors. Compounds 3c, d, and 3g-i produced potent antinociceptive activity in the rat formalin assay (i.paw) and the mouse acetic acid-induced writhing assay (s.c.), with weak activity in the mouse platform sedation test. The peripheral restriction indices of 3e, d, 3g, and X were improved 2- to 7-fold compared to the parent compound 1, and these compounds were approximately 2- to 5-fold more potent than the peripheral K agonist ICI 204448. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.12.018
• 作为产物：
  描述：

  3-甲氧基苯甲醛 、 alkaline earth salt of/the/ methylsulfuric acid 在 sodium hydroxide 、 氯化铵 作用下， 生成 R,S-N-Methoxycarbonyl-2-(3-methoxyphenyl)-glycine
  参考文献：
  名称：

  Synthesis and evaluation of novel peripherally restricted κ-opioid receptor agonists

  摘要：

  A series of 3-substituted analogs (3) of the parent K agonist, 1, were prepared to limit access to the central nervous system. With the exception of compound 3j, all other compounds bound to the human K opioid receptor with high affinity (K-i = 0.31-9.5 nM) and were selective for K over mu and 6 opioid receptors. Compounds 3c, d, and 3g-i produced potent antinociceptive activity in the rat formalin assay (i.paw) and the mouse acetic acid-induced writhing assay (s.c.), with weak activity in the mouse platform sedation test. The peripheral restriction indices of 3e, d, 3g, and X were improved 2- to 7-fold compared to the parent compound 1, and these compounds were approximately 2- to 5-fold more potent than the peripheral K agonist ICI 204448. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.12.018

文献信息

• Kappa agonist compounds and pharmaceutical formulations thereof
  申请人：——

  公开号：US20030144272A1

  公开（公告）日：2003-07-31

  Compounds having kappa opioid agonist activity, compositions containing them and method of using them as analgesics are provided. The compounds of formulae I, II, IIA, III, IIIA, IIIB, IIIB-i, IV and IVA have the structure: 1 2 wherein R 1 , R 2 , R 3 , R 4 ; and X, X 4 , X 5 , X 7 , X 9 ; Y, Z and n are as described in the specification.

  提供具有kappa阿片受体激动剂活性的化合物，含有这些化合物的组合物以及使用它们作为镇痛剂的方法。 具有以下结构的化合物I、II、IIA、III、IIIA、IIIB、IIIB-i、IV和IVA： 1 2 其中 R 1 ，R 2 ，R 3 ，R 4 ；和 X，X 4 ，X 5 ，X 7 ，X 9 ； Y，Z和n如规范中所述。
• Kappa agonist compounds pharmaceutical formulations and method of
  申请人：Adolor Corporation

  公开号：US06057323A1

  公开（公告）日：2000-05-02

  Compounds having kappa opioid agonist activity, compositions containing them and method of using them as analgesics and anti-pruritic agents are provided. The compound of formula I, having the structure: ##STR1## wherein R.sub.1, R.sub.2 ; X; and Ar Y, Z and n are as described in the specification.

  提供具有kappa阿片受体激动剂活性的化合物、含有这些化合物的组合物以及将它们用作镇痛剂和抗瘙痒剂的方法。具有结构的I式化合物：##STR1##其中R.sub.1，R.sub.2；X；和Ar Y，Z和n如规范中描述。
• Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
  申请人：Adolor Corporation

  公开号：US06239154B1

  公开（公告）日：2001-05-29

  Method for the prevention or treatment of pruritis by administering to a patient an antipruritic compound, or pharmaceutically acceptable salt thereof, of the class arylacetamide, which is exemplified by compounds of the formulae I, II, IIA, III, IV and IVA having the structures: and in which R1-4, X, X4, X5, X7, X9, Y and Z are as described in the specification.

  通过向患者施用一种抗瘙痒化合物或其药用盐，以达到预防或治疗瘙痒的方法，所述化合物属于芳基乙酰胺类，该类化合物的示例包括具有以下结构的化合物：其中R1-4、X、X4、X5、X7、X9、Y和Z如规范中所述。
• Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith
  申请人：——

  公开号：US20020013296A1

  公开（公告）日：2002-01-31

  Method for the prevention or treatment of pruritus with anti-pruritic compounds is provided. The compounds of formulae I, II, IIA, III, IIIA, IV and IVA have the structure: 1 wherein R 1 , R 2 , R 3 , R 4 ; and X, X 4 , X 5 , X 7 , X 9 ; Y, Z and n are as described in the specification.

  本发明提供了使用抗瘙痒化合物预防或治疗瘙痒的方法。公式I、II、IIA、III、IIIA、IV和IVA的化合物具有以下结构：其中R1、R2、R3、R4；和X、X4、X5、X7、X9；Y、Z和n如规范中所述。
• ANTIVIRAL COMPOUNDS
  申请人：Bacon Elizabeth M.

  公开号：US20140018313A1

  公开（公告）日：2014-01-16

  The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

  本发明涉及抗病毒化合物、含有这种化合物的组合物、包括给予这种化合物的治疗方法，以及用于制备这种化合物的有用过程和中间体。